AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MPH Health Care

Earnings Release Mar 16, 2015

5425_rns_2015-03-16_63157dba-3c19-4702-ad3a-b9a08717e825.html

Earnings Release

Open in Viewer

Opens in native device viewer

News Details

Corporate | 16 March 2015 10:10

MPH Mittelständische Pharma Holding AG: Preliminary IFRS results 2014, sales of EUR 219.24 million, net income of EUR 8.46 million

MPH Mittelständische Pharma Holding AG / Key word(s): Preliminary Results

2015-03-16 / 10:10


MPH Mittelständische Pharma Holding AG:

Preliminary IFRS results 2014, sales of EUR 219.24 million, net income of EUR 8.46 million

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0NF697), reports its preliminary IFRS Group results for the financial year 2014.

In the financial year 2014 the preliminary IFRS Group sales amounted to approximately EUR 219.24 million (previous year: EUR 226.84 million) and the preliminary IFRS consolidated net income was about EUR 8.46 million (previous year: EUR 7.49 million). The preliminary earnings per share reached EUR 0.19 (previous year: EUR 0.18).

The substance has been further strengthened. The preliminary IFRS equity increased to EUR 94.73 million (previous year: EUR 79.19 million). The liquidity position improved to EUR 10.12 million (previous year: EUR 5.85 million).

The business strategy of “making a contribution towards maintaining healthcare affordable” has paid off. In the healthcare market MPH AG is following this strategy with an attractive offer of medicines and medical services with focus on oncology and HIV in the health insurance reimbursed market and with focus on aesthetic medicine in the self-pay market.

About MPH Mittelständische Pharma Holding AG:

The company MPH Mittelständische Pharma Holding AG, based in Berlin, has strategically concentrated its activities on the growth segments Pharma and Healthcare. The pharmaceutical sector makes a contribution towards cutting costs in the healthcare system with medicines manufactured on the basis of patent-free and patent-protected active substances for the therapy of chronic diseases. The field of healthcare offers healthcare preparations, individual patient therapies, aesthetic surgeries and other medical treatments.

Key figures for the share of MPH Mittelständische Pharma Holding AG:

Subscribed capital: EUR 42,813,842

Listed shares: ordinary shares

ISIN: DE000A0L1H32

WKN: A0L1H3

Stock symbol: 93M

Contact: Linda Reichelt

MPH Mittelständische Pharma Holding AG

Fasanenstraße 77

D-10623 Berlin

Phone:+49 (0) 30 897308660 Fax:+49 (0) 30 897308669

E-Mail: [email protected] Web: www.mph-ag.de


2015-03-16 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: MPH Mittelständische Pharma Holding AG
Fasanenstraße 77
10623 Berlin
Germany
Phone: 030 / 897 308 660
Fax: 030 / 897 308 669
E-mail: [email protected]
Internet: www.mph-ag.de
ISIN: DE000A0L1H32
WKN: A0L1H3
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt
End of News DGAP News-Service
- - -
333387  2015-03-16

Talk to a Data Expert

Have a question? We'll get back to you promptly.